Accuray Inc. Hits New 52-Week High at $7.82 (ARAY)
Accuray (NASDAQ:ARAY)’s share price reached a new 52-week high during mid-day trading on Friday, AnalystRatings.Net reports. The stock traded as high as $7.82 and last traded at $7.79, with a volume of 886,627 shares traded. The stock had previously closed at $7.61.
A number of analysts have recently weighed in on ARAY shares. Analysts at JPMorgan Chase & Co. upgraded shares of Accuray from an “underweight” rating to a “neutral” rating in a research note to investors on Friday, September 20th. They now have a $8.00 price target on the stock. Separately, analysts at Dougherty & Co raised their price target on shares of Accuray from $7.50 to $8.00 in a research note to investors on Thursday, August 29th. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Finally, analysts at Brean Capital reiterated a “buy” rating on shares of Accuray in a research note to investors on Wednesday, August 28th. They now have a $9.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $7.63.
Accuray has a one year low of $3.76 and a one year high of $7.73. The stock’s 50-day moving average is $7.03 and its 200-day moving average is $5.83. The company’s market cap is $582.7 million.
Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Tuesday, August 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20). The company had revenue of $84.90 million for the quarter, compared to the consensus estimate of $82.29 million. During the same quarter in the prior year, the company posted ($0.20) earnings per share. The company’s quarterly revenue was down 15.5% on a year-over-year basis. On average, analysts predict that Accuray will post $-0.63 earnings per share for the current fiscal year.
Accuray, Inc manufactures image-guided radiosurgery devices. The Company is based in the United States and its core product, the CyberKnife Stereotactic Radiosurgery System, combines image-guidance with robotics to offer unparalleled flexibility and accuracy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.